Fresenius Medical Care Showcases Breadth & Depth of Clinical Research with Nearly 70 Abstracts Slated for Presentation at the...
November 17 2016 - 2:24PM
Business Wire
Clinical Findings Underscore Company’s
Leadership in Advancing the Science Behind Understanding Renal and
Chronic Disease Care
Fresenius Medical Care North America (FMCNA), the continent’s
leading provider of kidney care products and services, today
announced that the American Society of Nephrology (ASN) accepted a
total of 66 abstracts authored by the company’s researchers,
clinicians, and caregivers for presentation at the 2016 Kidney Week
Meeting and publication in the Abstract Supplement of Journal of
the American Society of Nephrology (JASN). The general meeting is
scheduled from November 17th through November 20th in Chicago and
is expected to attract more than 13,000 leading kidney
professionals from around the world.
“The unmatched breadth and depth of our clinical research plays
an important role in advancing the scientific understanding of
renal and chronic disease care and demonstrates our commitment to
improving the lives of our patients,” said Dr. Frank Maddux, FMCNA
Chief Medical Officer and Executive Vice President for Clinical and
Scientific Affairs. “Our research endeavors draw on the strength of
the FMCNA global research footprint, and are a distinct competitive
advantage in our ability to innovate the future of integrated renal
care.”
Of the 66 abstracts to be presented from Fresenius Medical Care
globally, 56 originate from Fresenius Medical Care North America,
with an additional 10 abstracts presented as Fresenius Medical Care
sponsored research. Overall, 76 abstracts associated with Fresenius
Medical Care will be displayed at the ASN 2016 Kidney Week
symposium.
These presentations are efforts aimed to enhance quality of life
and outcomes of care delivered to patients with chronic kidney
diseases and fall into eight categories:
- Using science and technology to improve
patient outcomes
- Characterizing and enhancing renal care
in incident dialysis
- Implementing initiatives to improve
vascular access care in hemodialysis patients
- Leveraging coordinated and transitional
care initiatives to better health outcomes
- Identifying disparities and customizing
therapies to the patients’ geographic locations
- Discerning patient profiles during
progression from CKD to ESRD
- Understanding psychosocial parameters
in renal disease and associations in outcomes
- Designing and utilizing predictive
models for enhancement of renal care paradigms
Highlights of key presentations at the ASN Kidney Week Meeting
involving the organization’s staff include:
- Quantifying Risk of Increased
All-Cause Hospitalization for Adult Hemodialysis Patients Who
Skipped Seasonal Flu Vaccination. This study investigated the
impact of missing or refusing annual inoculation against seasonal
influenza on hospitalization rates and risk. This oral presentation
(FR-OR079) will be given by Nien-Chen Li, MS, MPH Biostatistician,
Custom Reporting and Data Analysis, FMCNA.
- Geography, Life Expectancy in the
General Population, and the Age of Mortality in Dialysis
Patients. This study investigated whether geographical
disparities exist for the age of mortality in dialysis patients and
compared them to the respective life expectancy of the general
population. This poster (SA-PO928) will be presented by Peiran
“Peter” Yu, MA, Data Scientist, Integrated Care Analytics,
FMCNA.
- Central Venous Oxygen Saturation as
a Novel Means to Monitor Arterio-Venous Fistula Maturation.
This study investigated whether the central venous oxygen
saturation changes in hemodialysis patients proximal to the
creation and maturation of arteriovenous fistula. This poster
(TH-PO1088) will be presented by Israel Campos, MD, Senior Research
Fellow, Renal Research Institute.
- Profiles of Quality of Life in Home
and In-Center Dialysis Patients in a Large National Population.
This study investigated if Kidney Disease Quality of Life (KDQOL)
survey scores differ among dialysis patients treated by a home
modality versus those treated by in-center hemodialysis. This
poster (SA-PO1127) will be presented by FMCNA’s collaborator
Nwamaka Eneanya, MD, MPH, Investigator, Division of Nephrology,
Massachusetts General Hospital.
FMCNA research is an ongoing endeavor throughout the year: in
the first quarter of 2016 alone, FMCNA had 20 published journal
articles, and since 2015, its research has included more than 125
abstracts accepted, involving the contributions of more than 1,200
FMCNA staff members. As the largest and most comprehensive
integrated renal care company in North America, FMCNA is unmatched
in its ability to gather and analyze immense amounts of patient
data from within the company’s own care ecosystem.
With the nature of dialysis care allowing FMCNA to collect large
amounts of patient data during routine treatments, the company has
collected data on more than 1 million patients, including data on
more than 250 million dialysis treatments, more than 1 billion
medication administrations and over 1 billion laboratory
results.
“Research, data and analytics are the innovation engines that
inform every aspect of our direct patient care, quality improvement
programs, coordinated care delivery and care integration,” Maddux
said. “The researchers at Fresenius Medical Care are helping to
create the very roadmap that will continue to drive the future of
renal care.”
About Fresenius Medical Care North AmericaFresenius
Medical Care North America is the premier health care company
focused on providing the highest quality care to people with renal
and other chronic conditions. Through its industry-leading network
of dialysis facilities, outpatient cardiac and vascular labs, and
urgent care centers, as well as the country’s largest practice of
hospitalist and post-acute providers, Fresenius Medical Care
provides coordinated health care services at pivotal care points
for hundreds of thousands of chronically ill customers throughout
the continent. As the world’s largest fully integrated renal
company, it offers specialty pharmacy and laboratory services, and
manufactures and distributes the most comprehensive line of
dialysis equipment, disposable products, and renal pharmaceuticals.
For more information, visit the FMCNA website at www.fmcna.com. For
information about patient services, visit
www.freseniuskidneycare.com.
About the American Society of NephrologyFounded in 1966,
the American Society of Nephrology (ASN) is the world’s largest
professional society devoted to the study of kidney disease. With
15,000 physician and scientist members, ASN leads the fight against
kidney disease by educating health professionals, sharing new
knowledge, advancing research, and advocating the highest quality
care for patients. ASN also informs policymakers about issues of
importance to kidney doctors and their patients. ASN funds
research, and through its world-renowned meetings and first-class
publications, disseminates information and educational tools that
empower physicians. For more information about the society, visit
www.asn-online.org/.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161117006230/en/
Fresenius Medical Care North AmericaJon Stone,
781-392-4680Jonathan.d.stone@fmc-na.com
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2023 to Apr 2024